Nothing Special   »   [go: up one dir, main page]

MX2021003027A - Compuesto de imidazopiridinona. - Google Patents

Compuesto de imidazopiridinona.

Info

Publication number
MX2021003027A
MX2021003027A MX2021003027A MX2021003027A MX2021003027A MX 2021003027 A MX2021003027 A MX 2021003027A MX 2021003027 A MX2021003027 A MX 2021003027A MX 2021003027 A MX2021003027 A MX 2021003027A MX 2021003027 A MX2021003027 A MX 2021003027A
Authority
MX
Mexico
Prior art keywords
present
compound
inflammatory bowel
bowel diseases
useful
Prior art date
Application number
MX2021003027A
Other languages
English (en)
Inventor
Akihiro Moriyama
Yasushi Takigawa
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of MX2021003027A publication Critical patent/MX2021003027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se enfoca en proporcionar un compuesto novedoso con un efecto inhibitorio de prolil hidroxilasa (PHD) y que es útil para el tratamiento de enfermedades intestinales inflamatorias como colitis ulcerosa y similares. La presente invención se relaciona con un compuesto de imidazopiridinona representado por la siguiente fórmula (I) o una sal farmacéuticamente aceptable del mismo. Los compuestos de la presente invención o sales farmacéuticamente aceptables de los mismos que tienen un efecto inhibitorio de prolil hidroxilasa y son útiles como agentes para el tratamiento de enfermedades intestinales inflamatorias como colitis ulcerosa y similares. En una modalidad, la presente invención se relaciona con un método para tratar una enfermedad intestinal inflamatoria. (ver Fórmula).
MX2021003027A 2018-09-13 2019-09-12 Compuesto de imidazopiridinona. MX2021003027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018171839 2018-09-13
PCT/JP2019/035792 WO2020054788A1 (ja) 2018-09-13 2019-09-12 イミダゾピリジノン化合物

Publications (1)

Publication Number Publication Date
MX2021003027A true MX2021003027A (es) 2021-05-27

Family

ID=69777067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003027A MX2021003027A (es) 2018-09-13 2019-09-12 Compuesto de imidazopiridinona.

Country Status (16)

Country Link
US (1) US12077531B2 (es)
EP (1) EP3808747A4 (es)
JP (1) JP7458987B2 (es)
KR (1) KR20210057014A (es)
CN (1) CN112689637B (es)
AR (1) AR116400A1 (es)
AU (1) AU2019340173B2 (es)
BR (1) BR112021004730A2 (es)
CA (1) CA3106385A1 (es)
IL (1) IL281391A (es)
MX (1) MX2021003027A (es)
PH (1) PH12021550512A1 (es)
SG (1) SG11202102441VA (es)
TW (1) TWI814903B (es)
WO (1) WO2020054788A1 (es)
ZA (1) ZA202101671B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414550B2 (ja) * 2020-01-23 2024-01-16 キッセイ薬品工業株式会社 （ヘテロ）アリールイミダゾロン化合物
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN115279761A (zh) * 2020-03-11 2022-11-01 橘生药品工业株式会社 咪唑并吡啶酮化合物或其盐的晶体
CN117402178B (zh) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶类化合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650961B1 (de) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
IL141866A0 (en) 1998-09-18 2002-03-10 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
CN1849319A (zh) * 2003-07-23 2006-10-18 惠氏公司 作为5－羟色胺－6配体的磺酰基二氢咪唑并吡啶酮化合物
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
CN1984901B (zh) * 2004-05-18 2011-02-09 先灵公司 用作pde4抑制剂的取代的2-喹啉基-*唑
CA2601458C (en) 2005-03-15 2011-04-26 Pfizer Inc. Benzimidazolone derivatives as cb2 receptor ligands
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007015877A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2008032164A2 (en) * 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
WO2008143674A1 (en) * 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US20090069319A1 (en) 2007-08-27 2009-03-12 Wyeth Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
US8471024B2 (en) * 2008-02-25 2013-06-25 Merck Sharp & Dohme, Corp. Tetrahydrofuropyridones
ES2523720T3 (es) * 2008-04-28 2014-12-01 Janssen Pharmaceutica, N.V. Benzoimidazoles como inhibidores de prolilhidroxilasa
WO2009137291A2 (en) * 2008-05-08 2009-11-12 Merck & Co., Inc. Spiroazaindoles
CA2736522C (en) * 2008-09-09 2016-09-13 Boehringer Ingelheim International Gmbh Aza-benzimidazolone chymase inhibitors
CN102471337B (zh) * 2009-07-17 2014-12-10 日本烟草产业株式会社 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用
JP2011037814A (ja) * 2009-08-14 2011-02-24 Synstar Japan Co Ltd マラリア原虫疾患予防又は治療用の５−ヘテロ環置換イミノ−９−ジアルキルアミノベンゾ［ａ］フェノキサチン化合物又はその塩とアーテミシニン誘導体との組み合わせ
WO2011096490A1 (ja) * 2010-02-04 2011-08-11 第一三共株式会社 イミダゾピリジン－２－オン誘導体
WO2014181813A1 (ja) * 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
CN105723303B (zh) * 2013-10-08 2019-01-22 麦克赛尔株式会社 投影型影像显示装置、操作检测装置及投影型影像显示方法
WO2015052675A1 (en) * 2013-10-10 2015-04-16 Glenmark Pharmaceuticals S.A. Substituted dihydro-benzimidazole compounds as ror gamma modulators
CN104926733B (zh) * 2014-03-18 2019-05-10 北京韩美药品有限公司 作为RORγ调节剂的化合物
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
KR102666352B1 (ko) * 2015-06-03 2024-05-17 프린시피아 바이오파마, 인코퍼레이티드 티로신 키나제 억제제
US10358446B2 (en) * 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
CA3034785C (en) 2016-08-22 2022-11-15 Shijiazhuang Sagacity New Drug Development Co., Ltd. Pde4 inhibitor
US10899758B2 (en) * 2016-09-16 2021-01-26 Vitae Pharmaceuticals, Llc Inhibitors of the menin-MLL interaction
CN111615513A (zh) * 2018-01-19 2020-09-01 爱杜西亚药品有限公司 C5a受体调节剂

Also Published As

Publication number Publication date
US12077531B2 (en) 2024-09-03
WO2020054788A1 (ja) 2020-03-19
ZA202101671B (en) 2022-07-27
TWI814903B (zh) 2023-09-11
US20210206765A1 (en) 2021-07-08
CN112689637B (zh) 2023-11-10
KR20210057014A (ko) 2021-05-20
CA3106385A1 (en) 2020-03-19
CN112689637A (zh) 2021-04-20
JPWO2020054788A1 (ja) 2021-08-30
TW202024077A (zh) 2020-07-01
BR112021004730A2 (pt) 2021-06-01
AU2019340173A1 (en) 2021-04-08
PH12021550512A1 (en) 2022-02-21
AR116400A1 (es) 2021-05-05
EP3808747A1 (en) 2021-04-21
SG11202102441VA (en) 2021-04-29
IL281391A (en) 2021-04-29
EP3808747A4 (en) 2022-03-09
JP7458987B2 (ja) 2024-04-01
AU2019340173B2 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
PH12021550512A1 (en) Imidazopyridinone compound
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
EA201990833A1 (ru) Соединение пиридина
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
EA202193015A1 (ru) Ингибиторы cdk
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
EA202090900A1 (ru) Ингибиторы иммунопротеасом
PH12019502248A1 (en) Ip6k inhibitors
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
BR112022001922A2 (pt) Compostos de heteroarila de anel fundido como inibidores de ripk1
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
AU2018337138A1 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
MX2021011081A (es) Derivados de nicorandil.
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer
PH12019502261A1 (en) Therapeutic or prophylactic agent for peripheral neuropathies